A significant court decision has reinstated over 500 lawsuits claiming a connection between acetaminophen use during pregnancy and autism spectrum disorder in children. The ruling allows cases against Kenvue, the manufacturer of Tylenol, to proceed despite previous dismissals citing insufficient scientific evidence. This legal development marks a pivotal moment in product liability litigation, potentially opening pathways for plaintiffs to present emerging research and expert testimony regarding potential links between prenatal acetaminophen exposure and neurodevelopmental outcomes.

Summary auto-generated by AI from the original publisher's content. Editorial standards.